Point-of-care blood eosinophil count in a severe asthma clinic setting.

Background: One of the main severe asthma phenotypes is severe eosinophilic or eosinophilic refractory asthma for which novel biologic agents are emerging as therapeutic options. In this context, blood eosinophil counts are one of the most reliable biomarkers.

Objective: To evaluate the performance of a point-of-care peripheral blood counter in a patients with severe asthma.